Maze Therapeutics (MAZE) Free Cash Flow (2024 - 2026)
Maze Therapeutics (MAZE) reported Free Cash Flow of -$39.2 million for Q1 2026, down 31.5% on a YoY basis from -$57.2 million in Q1 2025, and down 37.61% sequentially from -$28.5 million in Q4 2025.
Maze Therapeutics (MAZE) Free Cash Flow (2024 - 2026) Analysis & Trends
Maze Therapeutics (MAZE) has 3 years of Free Cash Flow data on file, last reported at -$39.2 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 31.5% year-over-year to -$39.2 million; the trailing twelve-month figure through Mar 2026 stood at -$122.1 million (down 277.74% YoY), and the FY2025 full-year result was -$112.7 million, down 250.7% from the prior year.
- Free Cash Flow eased to -$39.2 million in Q1 2026, from -$28.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $145.3 million in Q2 2024 to a low of -$39.2 million in Q1 2026.
- A 3-year average of -$8.6 million and a median of -$24.0 million in 2025 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 2.58% in 2025, while the deepest fall reached 120.95% in 2025.
- Tracing MAZE's Free Cash Flow over 3 years: stood at -$23.4 million in 2024, then decreased by 21.8% to -$28.5 million in 2025, then plunged by 37.61% to -$39.2 million in 2026.
- Business Quant data shows MAZE's Free Cash Flow at -$39.2 million in Q1 2026, -$28.5 million in Q4 2025, and -$24.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | -39.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.21 Mn |
| Mar 31, 2026 | -39.21 Mn |
| Dec 31, 2025 | -28.49 Mn |
| Dec 31, 2025 | -28.49 Mn |
| Sep 30, 2025 | -23.98 Mn |
| Sep 30, 2025 | -23.98 Mn |
| Jun 30, 2025 | -30.45 Mn |
| Jun 30, 2025 | -30.45 Mn |
| Mar 31, 2025 | -29.82 Mn |
| Mar 31, 2025 | -29.82 Mn |
| Dec 31, 2024 | -23.39 Mn |
| Dec 31, 2024 | -23.39 Mn |
| Sep 30, 2024 | -23.38 Mn |
| Sep 30, 2024 | -23.38 Mn |
| Jun 30, 2024 | 145.30 Mn |
| Jun 30, 2024 | 145.30 Mn |
| Mar 31, 2024 | -23.72 Mn |
| Mar 31, 2024 | -23.72 Mn |